Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
复制标题
DOI：
10.1016/j.cell.2017.01.017
复制
发表时间：
2017-02-09
期刊：
影响因子：
64.5
通讯作者：
Ribas A
中科院分区：
文献类型：
--
作者：
Sharma P;Hu-Lieskovan S;Wargo JA;Ribas A
Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are being elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
